130 related articles for article (PubMed ID: 31780055)
41. Nuclear C-MYC expression level is associated with disease progression and potentially predictive of two year overall survival in prostate cancer.
Zeng W; Sun H; Meng F; Liu Z; Xiong J; Zhou S; Li F; Hu J; Hu Z; Liu Z
Int J Clin Exp Pathol; 2015; 8(2):1878-88. PubMed ID: 25973080
[TBL] [Abstract][Full Text] [Related]
42. Development and validation of hub genes for lymph node metastasis in patients with prostate cancer.
Xu N; Chen SH; Lin TT; Cai H; Ke ZB; Dong RN; Huang P; Li XD; Chen YH; Zheng QS
J Cell Mol Med; 2020 Apr; 24(8):4402-4414. PubMed ID: 32130760
[TBL] [Abstract][Full Text] [Related]
43. MicroRNA-224 inhibits progression of human prostate cancer by downregulating TRIB1.
Lin ZY; Huang YQ; Zhang YQ; Han ZD; He HC; Ling XH; Fu X; Dai QS; Cai C; Chen JH; Liang YX; Jiang FN; Zhong WD; Wang F; Wu CL
Int J Cancer; 2014 Aug; 135(3):541-50. PubMed ID: 24382668
[TBL] [Abstract][Full Text] [Related]
44. The role of ATP-binding cassette transporter genes in the progression of prostate cancer.
Karatas OF; Guzel E; Duz MB; Ittmann M; Ozen M
Prostate; 2016 Apr; 76(5):434-44. PubMed ID: 26708806
[TBL] [Abstract][Full Text] [Related]
45. High expression of DDX20 enhances the proliferation and metastatic potential of prostate cancer cells through the NF-κB pathway.
Chen W; Zhou P; Li X
Int J Mol Med; 2016 Jun; 37(6):1551-7. PubMed ID: 27121695
[TBL] [Abstract][Full Text] [Related]
46. The prognostic impact of tumour NSD2 expression in advanced prostate cancer.
Stangl-Kremser J; Lemberger U; Hassler MR; Garstka N; Grubmüller B; Haitel A; Enikeev DV; Glybochko PV; Kramer G; Susani M; Shariat SF
Biomarkers; 2020 May; 25(3):268-273. PubMed ID: 32091270
[No Abstract] [Full Text] [Related]
47. TP73 is a credible biomarker for predicting clinical progression and prognosis in cervical cancer patients.
Ye H; Guo X
Biosci Rep; 2019 Aug; 39(8):. PubMed ID: 31332036
[TBL] [Abstract][Full Text] [Related]
48. Increased expression of elongation factor-1α is significantly correlated with poor prognosis of human prostate cancer.
Liu H; Ding J; Chen F; Fan B; Gao N; Yang Z; Qi L
Scand J Urol Nephrol; 2010 Nov; 44(5):277-83. PubMed ID: 20545466
[TBL] [Abstract][Full Text] [Related]
49. Asporin is a stromally expressed marker associated with prostate cancer progression.
Rochette A; Boufaied N; Scarlata E; Hamel L; Brimo F; Whitaker HC; Ramos-Montoya A; Neal DE; Dragomir A; Aprikian A; Chevalier S; Thomson AA
Br J Cancer; 2017 Mar; 116(6):775-784. PubMed ID: 28152543
[TBL] [Abstract][Full Text] [Related]
50. Outcome predictors of radical cystectomy in patients with cT4 prostate cancer: a multi-institutional study of 62 patients.
Spahn M; Morlacco A; Boxler S; Joniau S; Briganti A; Montorsi F; Gontero P; Bader P; Frohneberg D; van Poppel H; Karnes RJ;
BJU Int; 2017 Nov; 120(5B):E52-E58. PubMed ID: 28220605
[TBL] [Abstract][Full Text] [Related]
51. MAZ promotes prostate cancer bone metastasis through transcriptionally activating the KRas-dependent RalGEFs pathway.
Yang Q; Lang C; Wu Z; Dai Y; He S; Guo W; Huang S; Du H; Ren D; Peng X
J Exp Clin Cancer Res; 2019 Sep; 38(1):391. PubMed ID: 31488180
[TBL] [Abstract][Full Text] [Related]
52. Downregulation of miR-129 in peripheral blood mononuclear cells is a diagnostic and prognostic biomarker in prostate cancer.
Xu S; Yi XM; Zhou WQ; Cheng W; Ge JP; Zhang ZY
Int J Clin Exp Pathol; 2015; 8(11):14335-44. PubMed ID: 26823749
[TBL] [Abstract][Full Text] [Related]
53. Estrogen induces androgen-repressed SOX4 expression to promote progression of prostate cancer cells.
Yang M; Wang J; Wang L; Shen C; Su B; Qi M; Hu J; Gao W; Tan W; Han B
Prostate; 2015 Sep; 75(13):1363-75. PubMed ID: 26015225
[TBL] [Abstract][Full Text] [Related]
54. High levels of DEPDC1B predict shorter biochemical recurrence-free survival of patients with prostate cancer.
Bai S; Chen T; Du T; Chen X; Lai Y; Ma X; Wu W; Lin C; Liu L; Huang H
Oncol Lett; 2017 Dec; 14(6):6801-6808. PubMed ID: 29163701
[TBL] [Abstract][Full Text] [Related]
55. Human PDE4D isoform composition is deregulated in primary prostate cancer and indicative for disease progression and development of distant metastases.
Böttcher R; Dulla K; van Strijp D; Dits N; Verhoef EI; Baillie GS; van Leenders GJ; Houslay MD; Jenster G; Hoffmann R
Oncotarget; 2016 Oct; 7(43):70669-70684. PubMed ID: 27683107
[TBL] [Abstract][Full Text] [Related]
56. Protein regulator of cytokinesis 1 overexpression predicts biochemical recurrence in men with prostate cancer.
Luo HW; Chen QB; Wan YP; Chen GX; Zhuo YJ; Cai ZD; Luo Z; Han ZD; Liang YX; Zhong WD
Biomed Pharmacother; 2016 Mar; 78():116-120. PubMed ID: 26898432
[TBL] [Abstract][Full Text] [Related]
57. SNORA42 enhances prostate cancer cell viability, migration and EMT and is correlated with prostate cancer poor prognosis.
Yi C; Wan X; Zhang Y; Fu F; Zhao C; Qin R; Wu H; Li Y; Huang Y
Int J Biochem Cell Biol; 2018 Sep; 102():138-150. PubMed ID: 30053504
[TBL] [Abstract][Full Text] [Related]
58. MPC1 and MPC2 expressions are associated with favorable clinical outcomes in prostate cancer.
Li X; Ji Y; Han G; Li X; Fan Z; Li Y; Zhong Y; Cao J; Zhao J; Zhang M; Wen J; Goscinski MA; Nesland JM; Suo Z
BMC Cancer; 2016 Nov; 16(1):894. PubMed ID: 27852261
[TBL] [Abstract][Full Text] [Related]
59. The role of HOXC6 in prostate cancer development.
Hamid AR; Hoogland AM; Smit F; Jannink S; van Rijt-van de Westerlo C; Jansen CF; van Leenders GJ; Verhaegh GW; Schalken JA
Prostate; 2015 Dec; 75(16):1868-76. PubMed ID: 26310814
[TBL] [Abstract][Full Text] [Related]
60. Immune checkpoint-related serum proteins and genetic variants predict outcomes of localized prostate cancer, a cohort study.
Wang Q; Ye Y; Yu H; Lin SH; Tu H; Liang D; Chang DW; Huang M; Wu X
Cancer Immunol Immunother; 2021 Mar; 70(3):701-712. PubMed ID: 32909077
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
